Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus

Autoimmune Disease

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Lancet.

van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S

doi: 10.1016/S0140-

Autoimmune DiseaseSystemic Lupus ErythematosusFurther Publications Rheumatology

EMBRACE: Phase 3/4, Randomized, 52-Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Arthritis Rheumatol

Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B, At the time of the study.

doi: 10.1002/art.41900

Systemic Lupus Erythematosus

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus

Lupus.

Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y

doi: 10.1177/0961203317749047.

Systemic Lupus Erythematosus

Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study.

Arthritis Rheumatol.

Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D

doi: 10.1002/art.40049.

Systemic Lupus Erythematosus

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

Ann Rheum Dis.

Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

doi: 10.1136/annrheumdis-2020-217101.

Systemic Lupus Erythematosus

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus

Autoimmun Rev.

Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Rönnelid J, Malmström V, Bengtsson AA, Gunnarsson I

doi: 10.1016/j.autrev.2017.02.005.

Systemic Lupus Erythematosus

Impact of multiple sclerosis on quality of life: Comparison with systemic lupus erythematosus

Clin Neurol Neurosurg.

Carnero Contentti E, Genco ND, Hryb JP, Caspi M, Chiganer E, Di Pace JL, López PA, Lessa C, Caride A, Perassolo M

doi: 10.1016/

Autoimmune Disease

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Autoimmun Rev.

Bragazzi NL, McGonagle D, Watad S, Adawi M, Mahroum N, Damiani G, Conic R, Bridgewood C, Mahagna H, Giacomelli L, Eggenhöffner R, Mahamid M, Pigatto PDM, Amital H, Watad A

doi: 10.1016/j.autrev.2018.08.002.

ImmunomodulationSystemic Lupus Erythematosus

Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus

Lupus.

Prete M, Leone P, Frassanito MA, Desantis V, Marasco C, Cicco S, Dammacco F, Vacca A, Racanelli V

doi: 10.1177/0961203318797425.

Related content

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

EMBRACE: Phase 3/4, Randomized, 52-Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus

Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study.

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus

Impact of multiple sclerosis on quality of life: Comparison with systemic lupus erythematosus

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus